Authors

Latest:

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLC

Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.

Claud Grigg, MD

Latest:

Dr. Grigg Discusses CABOSUN Trial in mRCC

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.

Claud M. Grigg Jr, MD

Latest:

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Claude Denham, MD

Latest:

Dr. Denham on Hyperprogression in Patients With NSCLC

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Claudia Henschke, MD, PhD

Latest:

Lung Cancer Screening Needs to Remain State-of-the-Art

In CT screening for lung cancer, the regimen of screening is a critical factor in diagnosing lung cancer early while limiting unnecessary tests and invasive procedures.

Claudine Isaacs, MD

Latest:

Dr. Isaacs on the Evolving Treatment Landscape in HER2+ Breast Cancer

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

Latest:

Decision Factors for SubQ Therapy and Unmet Needs

Claudine J. Isaacs, MD, Lombardi Comprehensive Cancer Center

Claudio Anasetti, MD

Latest:

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Claus-Henning KÃ¶hne, MD, PhD, Klinikum Oldenburg

Clayton S. Lau, MD

Latest:

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Clemens A. Schmitt, MD

Latest:

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Clemens Krepler, MD

Latest:

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.

Clifford A. Hudis, MD

Latest:

Dr. Hudis on Combating Obesity in Breast Cancer

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Clinical Consulting, ION Solutions, a part of AmerisourceBergen

Latest:

What Oncologists Need to Know About USP and the Recent Clarification

Patients with cancer across the country rely on community oncology practices to provide them with high-quality, coordinated cancer care.

Colin G. Evans, PhD

Latest:

Preventing and Treating Bone Metastases in mCRPC

Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Colleen M. Danielson, NP, Massachusetts General Hospital

Colleen OLeary, MSN

Latest:

Colleen O'Leary Describes Chemotherapy Safety

Colleen OLeary from James Cancer Hospital Describes Chemotherapy Safety Standards

Colleen S. Delaney, MD, MSC

Latest:

No Need to Wait for the Perfect Match-Cord Blood Is Saving Time and Lives

The perception that cord blood is an inferior source of stem cells is simply not accurate and may result in delays in lifesaving treatment for patients.

Conleth Murphy, MD

Latest:

The Year in Breast Cancer: The Top Five Under-appreciated Developments of 2008